Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FBT-N101 + aflibercept
- Development stage
- Preclinical
- Lead developer
- Fusion Biotechnology
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravitreal
01
Overview
FBT-N101 + aflibercept (also referred to as FBT-N101 + Eylea) is an investigational combination therapy being developed by FusionBioTech for the treatment of wet age-related macular degeneration (wet AMD). The combination consists of FBT-N101, a small molecule MDM2 inhibitor, and aflibercept, a recombinant fusion protein that acts as a decoy receptor for vascular endothelial growth factor (VEGF). FBT-N101 functions as a senolytic agent by disrupting the MDM2-p53 interaction, thereby selectively inducing apoptosis in senescent retinal cells to address the underlying cellular aging process. Aflibercept inhibits angiogenesis and vascular permeability by binding to VEGF-A, VEGF-B, and placental growth factor (PlGF). By combining senolytic therapy with anti-VEGF therapy, this combination aims to provide a synergistic therapeutic effect for patients with wet AMD.
- Other names
- FBT-N101 + EyleaFBT-N101+Eyleaaflibercept + FBT-N101
02
Targets
VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)MDM2 (Mouse double minute 2 homolog)PGF (Placental Growth Factor)TP53 (Cellular Tumor Antigen p53 R175H)VEGFA (Vascular endothelial growth factor A)VEGFB (Vascular endothelial growth factor B)
Beyond the preview
Go deeper on FBT-N101 + aflibercept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FBT-N101 + aflibercept.